MarketPulse

deal fairness

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Juan Monteverde, Monteverde & Associates Pc

Class Action Probe Launched Into Esperion's $3.16 ARCHIMED Deal

Class action firm investigates Esperion Therapeutics' $3.16-per-share ARCHIMED sale, questioning deal fairness to shareholders.
ESPRacquisitionclass action
GlobeNewswire Inc.GlobeNewswire Inc.··Monteverde & Associates Pc

Class Action Firm Probes XOMA-Ligand Deal: Shareholders Question $39 Acquisition Price

Monteverde & Associates investigates XOMA Royalty's $39-per-share sale to Ligand Pharmaceuticals, questioning whether terms are fair to shareholders.
LGNDXOMAXOMAOXOMAPHLX+3acquisitionclass action
GlobeNewswire Inc.GlobeNewswire Inc.··Juan Monteverde

Class Action Probe Targets Galera-Obsidian Merger Over Shareholder Dilution Concerns

Class action firm investigates Galera-Obsidian merger, alleging unfair terms as Galera shareholders face 1.8% combined-company ownership post-deal.
GRTXclass actionmerger investigation
GlobeNewswire Inc.GlobeNewswire Inc.··Juan Monteverde

Class Action Probe Targets Leggett & Platt Acquisition Deal Value

Law firm Monteverde & Associates investigates $LEG acquisition by Somnigroup, questioning if 0.1455 share exchange ratio delivers fair shareholder value.
LEGSGIclass action lawsuitacquisition
BenzingaBenzinga··Monteverde & Associates Pc

Class Action Probe Targets HCB Financial Merger Deal Terms

Law firm investigates HCB Financial's merger with Independent Bank, questioning fairness of 1.59 share-plus-$17.51 cash consideration to shareholders.
IBCPHCBNclass actionmerger investigation
BenzingaBenzinga··Prnewswire

Law Firm Opens Investigation Into Roman DBDR's Merger With ThomasLloyd Climate Solutions

Law firm Monteverde & Associates investigates Roman DBDR's merger with ThomasLloyd Climate Solutions, questioning whether shareholders received adequate disclosure and fair transaction terms.
DRDBDRDBUDRDBWclass actionmerger investigation